Diamyd Medical is a Swedish listed company developing precision medicine drugs for type 1 diabetes and other forms of autoimmune diabetes. The development of the diabetes vaccine Diamyd has gotten furthest in the process and is in the last development before it can be launched on the market, provided that the phase III study goes according to plan.
As a sub-consultant for commmunications agency Narva Björn Raunio Information helped producing copy for Diamyd Medical’s annual report for its fiscal year 2020-2021. The work was done in close cooperation with the customer and Narva’s project manager. Texts were produced based on interviews with the company’s CEO, several employees and a member of the Board.